RGC (Regencell Bioscience Holdings) Debt-to-EBITDA : 0.00 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGC Regencell Bioscience Holdings Ltd RGC
33 GF Score
Price $5.03
! 2 Warning Signs
View Full Analysis

What is Regencell Bioscience Holdings Debt-to-EBITDA?

Regencell Bioscience Holdings RGC +5.80% 33 Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus rates RGC with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 690 Drug Manufacturers companies, Regencell Bioscience Holdings ranks worse than 144927.39% on this metric.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Regencell Bioscience Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.00 Mil. Regencell Bioscience Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was $0.00 Mil. Regencell Bioscience Holdings's annualized EBITDA for the quarter that ended in Dec. 2025 was $-10.68 Mil. Regencell Bioscience Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Regencell Bioscience Holdings's Debt-to-EBITDA or its related term are showing as below:

RGC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.33   Med: -0.16   Max: -0.02
Current: -0.08

During the past 7 years, the highest Debt-to-EBITDA Ratio of Regencell Bioscience Holdings was -0.02. The lowest was -5.33. And the median was -0.16.

RGC's Debt-to-EBITDA is ranked worse than
100% of 690 companies
in the Drug Manufacturers industry
Industry Median: 1.68 vs RGC: -0.08

Regencell Bioscience Holdings  (NAS:RGC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Regencell Bioscience Holdings Debt-to-EBITDA Related Terms

Regencell Bioscience Holdings Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Regencell Bioscience Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regencell Bioscience Holdings Debt-to-EBITDA Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-EBITDA
Get a 7-Day Free Trial -2.72 -0.11 -0.08 -0.02 -0.16

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.02 0.00 -0.15 0.00

RGC vs SUPN, BCRX, PBH: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Debt-to-EBITDA falls into.


RGC
33GF Score
Regencell Bioscience Holdings Ltd RGC
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regencell Bioscience Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Regencell Bioscience Holdings's Debt-to-EBITDA for the fiscal year that ended in Jun. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.313 + 0.232) / -3.377
=-0.16

Regencell Bioscience Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -10.68
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.00 mean?
Regencell Bioscience Holdings (RGC) has a Debt-to-EBITDA of 0.00 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Regencell Bioscience Holdings. According to the industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 690 companies in the Drug Manufacturers industry.
Is Regencell Bioscience Holdings' Debt-to-EBITDA too high?
Regencell Bioscience Holdings' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Regencell Bioscience Holdings ranks #999999 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Regencell Bioscience Holdings has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Regencell Bioscience Holdings' Debt-to-EBITDA compare to SUPN and BCRX?
According to the Drug Manufacturers industry distribution chart, Regencell Bioscience Holdings ranks #999999 out of 690 companies for Debt-to-EBITDA. This places Regencell Bioscience Holdings in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Regencell Bioscience Holdings. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regencell Bioscience Holdings's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regencell Bioscience Holdings stock overvalued right now?
Regencell Bioscience Holdings (RGC) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Regencell Bioscience Holdings' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Regencell Bioscience Holdings (RGC), the current Debt-to-EBITDA is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regencell Bioscience Holdings Business Description

Address 29 Leighton Road, 9th Floor, Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
33GF Score

Get the complete analysis for RGC

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.03
Price